|
1
|
Leung C, Yu C, Lin MI, Tognon C and
Bernatchez P: Expression of myoferlin in human and murine carcinoma
tumors, Role in membrane repair, cell proliferation and
tumorigenesis. Am J Pathol. 182:1900–1909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Achanzar WE and Ward S: A nematode gene
required for sperm vesicle fusion. J Cell Sci. 110:1073–1081.
1997.PubMed/NCBI
|
|
3
|
Ward S, Argon Y and Nelson GA: Sperm
morphogenesis in wild-type and fertilization-defective mutants of
Caenorhabditis elegans. J Cell Biol. 91:26–44. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Posey AD Jr, Pytel P, Gardikiotes K, et
al: Endocytic recycling proteins EHD1 and EHD2 interact with
fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J Biol Chem.
286:7379–7388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doherty KR, Cave A, Davis DB, Delmonte AJ,
Posey A, Earley JU, Hadhazy M and McNally EM: Normal myoblast
fusion requires myoferlin. Development. 132:5565–5575. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu C, Sharma A, Trane A, Utokaparch S,
Leung C and Bernatchez P: Myoferlin gene silencing decreases Tie-2
expression in vitro and angiogenesis in vivo. Vascul
Pharmacol. 55:26–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bernatchez PN, Acevedo L,
Fernandez-Hernando C, Murata T, Chalouni C, Kim J,
Erdjument-Bromage H, Shah V, Gratton JP, McNally EM, et al:
Myoferlin regulates vascular endothelial growth factor receptor-2
stability and function. J Biol Chem. 282:30745–30753. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li R, Ackerman WE 4th, Mihai C, Volakis
LI, Ghadiali S and Kniss DA: Myoferlin depletion in breast cancer
cells promotes mesenchymal to epithelial shape change and stalls
invasion. PLoS One. 7:e397662012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Volakis LI, Li R, Ackerman WE 4th, Mihai
C, Bechel M, Summerfield TL, Ahn CS, Powell HM, Zielinski R, Rosol
TJ, et al: Loss of myoferlin redirects breast cancer cell motility
towards collective migration. PLoS One. 9:e861102014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenberg MC, Kim Y, Li R, Ackerman WE,
Kniss DA and Friedman A: Mechanistic modeling of the effects of
myoferlin on tumor cell invasion. Proc Natl Acad Sci USA.
108:20078–20083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Turtoi A, Blomme A, Bellahcène A, Gilles
C, Hennequière V, Peixoto P, Bianchi E, Noel A, De Pauw E, Lifrange
E, et al: Myoferlin is a key regulator of EGFR activity in breast
cancer. Cancer Res. 73:5438–5448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang WS, Liu XH, Liu LX, Lou WH, Jin DY,
Yang PY and Wang XL: iTRAQ-based quantitative proteomics reveals
myoferlin as a novel prognostic predictor in pancreatic
adenocarcinoma. J Proteomics. 91:453–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leung C, Shaheen F, Bernatchez P and
Hackett TL: Expression of myoferlin in human airway epithelium and
its role in cell adhesion and zonula occludens-1 expression. PLoS
One. 7:e404782012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chheang S and Brown K: Lung cancer
staging: Clinical and radiologic perspectives. Semin Intervent
Radiol. 30:99–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ha SY and Roh MS: The new 2011
international association for the study of lung cancer/american
thoracic society/european respiratory society classification of
lung adenocarcinoma in resected specimens: Clinicopathologic
relevance and emerging issues. Korean J Pathol. 47:316–325. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki S, Dobashi Y, Sakurai H, Nishikawa
K, Hanawa M and Ooi A: Protein overexpression and gene
amplification of epidermal growth factor receptor in nonsmall cell
lung carcinomas. Histopathology. Cancer. 103:1265–1273. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee
CT and Chung JH: Alteration of the E-Cadherin/beta-Catenin Complex
is an independent poor prognostic factor in lung adenocarcinoma.
Korean J Pathol. 47:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rekhtman N, Ang DC, Sima CS, Travis WD and
Moreira AL: Immunohistochemical algorithm for differentiation of
lung adenocarcinoma and squamous cell carcinoma based on large
series of whole-tissue sections with validation in small specimens.
Mod Pathol. 24:1348–1359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jang I, Jeon BT, Jeong EA, Kim EJ, Kang D,
Lee JS, Jeong BG, Kim JH, Choi BH, Lee JE, et al:
Pak1/LIMK1/cofilin pathway contributes to tumor migration and
invasion in human non-small cell lung carcinomas and cell lines.
Korean J Physiol Pharmacol. 16:159–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morales-Oyarvide V and Mino-Kenudson M:
High-grade lung adenocarcinomas with micropapillary and/or solid
patterns: A review. Curr Opin Pulm Med. 20:317–323. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Z, Wang L, Eckloff BW, Deng B, Wang Y,
Wampfler JA, Jang J, Wieben ED, Jen J, You M and Yang P: Conserved
recurrent gene mutations correlate with pathway deregulation and
clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med
Genomics. 7:322014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lauro S, Onesti CE, Righini R and
Marchetti P: The use of bevacizumab in non-small cell lung cancer,
An update. Anticancer Res. 34:1537–1545. 2014.PubMed/NCBI
|
|
24
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rashdan S and Hanna N: Nintedanib for the
treatment of non-small-cell lung cancer. Expert Opin Pharmacother.
15:729–739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Majeti BK, Lee JH, Simmons BH and Shojaei
F: VEGF is an important mediator of tumor angiogenesis in malignant
lesions in a genetically engineered mouse model of lung
adenocarcinoma. BMC Cancer. 13:2132013. View Article : Google Scholar : PubMed/NCBI
|
